DK1341414T3 - Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter - Google Patents

Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter

Info

Publication number
DK1341414T3
DK1341414T3 DK01989109.2T DK01989109T DK1341414T3 DK 1341414 T3 DK1341414 T3 DK 1341414T3 DK 01989109 T DK01989109 T DK 01989109T DK 1341414 T3 DK1341414 T3 DK 1341414T3
Authority
DK
Denmark
Prior art keywords
marint
actinomycet
taxon
medicines
discovery
Prior art date
Application number
DK01989109.2T
Other languages
English (en)
Inventor
Tracy J Mincer
William Fenical
Paul R Jensen
Robert H R Feling
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1341414T3 publication Critical patent/DK1341414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/36—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK01989109.2T 2000-11-16 2001-11-16 Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter DK1341414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24935600P 2000-11-16 2000-11-16
PCT/US2001/043758 WO2002047610A2 (en) 2000-11-16 2001-11-16 Marine actinomycete taxon for drug and fermentation product dicovery

Publications (1)

Publication Number Publication Date
DK1341414T3 true DK1341414T3 (da) 2013-03-25

Family

ID=22943113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989109.2T DK1341414T3 (da) 2000-11-16 2001-11-16 Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter

Country Status (8)

Country Link
US (5) US7144723B2 (da)
EP (1) EP1341414B1 (da)
JP (2) JP4395549B2 (da)
AU (2) AU2002243228B2 (da)
CA (1) CA2429163C (da)
DK (1) DK1341414T3 (da)
ES (1) ES2402045T3 (da)
WO (1) WO2002047610A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP4795931B2 (ja) * 2003-02-14 2011-10-19 インターメッド・ディスカバリー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換複素環
EP2441767B1 (en) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamides and methods for use thereof
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
SI2441767T1 (sl) 2003-06-20 2015-10-30 The Regents Of The University Of California Salinosporamidi in metode za njihovo uporabo
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
EP1812443A2 (en) * 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
WO2007030662A1 (en) 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
US7465720B2 (en) * 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
KR20080109071A (ko) * 2006-04-06 2008-12-16 니리어스 파마슈티컬즈, 인코퍼레이션 살리노스포라마이드 ａ 및 그의 유도체들의 전합성
US20090325208A1 (en) * 2006-06-26 2009-12-31 Moore Bradley S Biosynthesis of Salinosporamide A and Analogs and Methods Thereof
US8986971B2 (en) 2006-09-22 2015-03-24 Triphase Research And Development I Corp. Salt formulations for the fermentation of marine microorganisms
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2262812A2 (en) 2008-03-07 2010-12-22 Nereus Pharmaceuticals, Inc. Total synthesis of salinosporamide a and analogs thereof
US20090285836A1 (en) * 2008-04-14 2009-11-19 Nereus Pharmaceuticals, Inc. Use of salinosporamide a to inhibit metastasis
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
WO2011133595A1 (en) 2010-04-19 2011-10-27 Massachusetts Institute Of Technology A polymer-nanostructure composition for selective molecular recognition
SG11201602283UA (en) * 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
US10213526B2 (en) 2014-03-21 2019-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
US10144719B1 (en) 2015-07-27 2018-12-04 University Of South Florida Antimicrobials from an epigenetics based fungal metabolite screening program
AU2017207015B2 (en) 2016-01-13 2022-08-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Vascular extracellular matrix hydrogel
WO2017210463A1 (en) 2016-06-01 2017-12-07 Celgene Tri A Holdings Ltd. Use of marizomib for the treatment of central nervous system (cns) cancers
EP3500576A1 (en) 2016-08-19 2019-06-26 Celgene International II Sàrl Morphic forms of marizomib and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
DE69320206T2 (de) 1992-11-27 1999-02-11 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
JP3844491B2 (ja) 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド ミコフェノール酸モフェチル高用量経口用懸濁剤
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6838477B2 (en) 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
WO1999006353A1 (fr) 1997-08-04 1999-02-11 Taisho Pharmaceutical Co., Ltd. Derives aryloxyaniline
AU749857B2 (en) 1997-08-15 2002-07-04 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
US20010051654A1 (en) 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
HUP0103460A3 (en) 1998-03-26 2002-11-28 Shionogi & Co Indole derivatives with antiviral activity and pharmaceutical compositions containing them
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
CA2347275C (en) 1998-10-20 2010-03-09 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4395549B2 (ja) 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
WO2003084551A1 (de) * 2002-04-05 2003-10-16 Viromics Gmbh Mittel zur behandlung von flaviviridae-infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7179834B2 (en) 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP4795931B2 (ja) 2003-02-14 2011-10-19 インターメッド・ディスカバリー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換複素環
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US7579371B2 (en) * 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20060264495A1 (en) * 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1812443A2 (en) * 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
ES2396762T3 (es) * 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
US20060287520A1 (en) * 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
WO2007030662A1 (en) 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
US8088923B2 (en) * 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
CN102089312A (zh) * 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物

Also Published As

Publication number Publication date
US7144723B2 (en) 2006-12-05
EP1341414A2 (en) 2003-09-10
AU2002243228B8 (en) 2002-06-24
US7879576B2 (en) 2011-02-01
WO2002047610A3 (en) 2002-10-10
AU4322802A (en) 2002-06-24
AU2002243228B2 (en) 2007-08-02
JP2004535766A (ja) 2004-12-02
JP2008119001A (ja) 2008-05-29
JP4395549B2 (ja) 2010-01-13
CA2429163A1 (en) 2002-06-20
CA2429163C (en) 2013-02-12
US20080070273A1 (en) 2008-03-20
EP1341414A4 (en) 2004-08-04
US20030157695A1 (en) 2003-08-21
US7928138B2 (en) 2011-04-19
US20060008852A1 (en) 2006-01-12
US20090197937A1 (en) 2009-08-06
WO2002047610A2 (en) 2002-06-20
ES2402045T3 (es) 2013-04-26
US20090069401A1 (en) 2009-03-12
EP1341414B1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
DK1341414T3 (da) Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter
ATE380814T1 (de) Kinaseinhibitoren als arzneimittel
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
NO20003968D0 (no) Farmasøytiske preparater
DK1282719T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20033556D0 (no) Farmasöytiske preparater
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
IS6724A (is) Aðferð til framleiðslu á N-arýl-anþranilískum sýrum og afleiðum þeirra
EE05020B1 (et) Glburiidi ravimkoostis
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20015399D0 (no) System og fremgangsmåte for produktdemontering
ITTO20000483A0 (it) Pannello termoformato e procedimento per la sua produzione.
DK1275397T3 (da) Lægemiddel til lokal anvendelse
NO20031408L (no) Modulering av transkripsjonen av pro-inflammatoriske genprodukter
DK1331972T3 (da) Farmaceutiske præparater
ITMI20001827A0 (it) Medicamento antinfiammatorio
NO20013735L (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
DK1339723T3 (da) Fremgangsmåde og ester derivater anvendelige til fremstilling af cefalosporiner
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
DK1263719T3 (da) N-deacetylthiocolchin-derivater og farmaceutiske sammensætninger indeholdende disse.
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DE60008237D1 (de) Lamivudin enthaltende arzneimittel
IS6618A (is) Hýgrómýsín A afleiður til meðhöndlunar á bakteríu- og frumdýrasýkingum